诺瓦瓦克斯医药公布了三项疫苗试验的积极结果

格隆汇资讯2023-05-09

格隆汇5月9日丨诺瓦瓦克斯医药(NVAX.US)公布了三项疫苗试验的积极结果，一项针对新冠和流感，一项针对独立流感，另一项大剂量的新冠疫苗。诺瓦瓦克斯医药说，所有三种候选药物在2期试验中都产生了强劲的免疫反应，并显示出令人放心的初步安全性。该公司表示：“与季节性流感疫苗Fluad相比，独立的流感候选疫苗在所有四种菌株中实现了具有统计学意义的血凝抑制(HAI)抗体反应的31％至56％。”最高剂量的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2334524465?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-05-09 19:40","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2334524465","market":"us","top_or_hot":-1,"title":"诺瓦瓦克斯医药公布了三项疫苗试验的积极结果","media":"格隆汇资讯","content":"<div>\n<p>格隆汇5月9日丨诺瓦瓦克斯医药(NVAX.US)公布了三项疫苗试验的积极结果，一项针对新冠和流感，一项针对独立流感，另一项大剂量的新冠疫苗。诺瓦瓦克斯医药说，所有三种候选药物在2期试验中都产生了强劲的免疫反应，并显示出令人放心的初步安全性。该公司表示：“与季节性流感疫苗Fluad相比，独立的流感候选疫苗在所有四种菌株中实现了具有统计学意义的血凝抑制(HAI)抗体反应的31％至56％。”最高剂量的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305091940448443af7c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺瓦瓦克斯医药公布了三项疫苗试验的积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺瓦瓦克斯医药公布了三项疫苗试验的积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-09 19:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305091940448443af7c&s=b><strong>格隆汇资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇5月9日丨诺瓦瓦克斯医药(NVAX.US)公布了三项疫苗试验的积极结果，一项针对新冠和流感，一项针对独立流感，另一项大剂量的新冠疫苗。诺瓦瓦克斯医药说，所有三种候选药物在2期试验中都产生了强劲的免疫反应，并显示出令人放心的初步安全性。该公司表示：“与季节性流感疫苗Fluad相比，独立的流感候选疫苗在所有四种菌株中实现了具有统计学意义的血凝抑制(HAI)抗体反应的31％至56％。”最高剂量的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305091940448443af7c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305091940448443af7c&s=b","article_id":"2334524465","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202305091940448443af7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2334524465","pubTimestamp":1683632434,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇5月9日丨诺瓦瓦克斯医药(NVAX.US)公布了三项疫苗试验的积极结果，一项针对新冠和流感，一项针对独立流感，另一项大剂量的新冠疫苗。诺瓦瓦克斯医药说，所有三种候选药物在2期试验中都产生了强劲的免疫反应，并显示出令人放心的初步安全性。该公司表示：“与季节性流感疫苗Fluad相比，独立的流感候选疫苗在所有四种菌株中实现了具有统计学意义的血凝抑制(HAI)抗体反应的31％至56％。”最高剂量的独立COVID疫苗取得了具有统计学意义的中和反应，比诺瓦瓦克斯医药的原型新冠疫苗高出约30％。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4568":"美国抗疫概念","NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax Pharmaceuticals publishes positive results from three vaccine trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"格隆汇5月9日丨诺瓦瓦克斯医药(NVAX.US)公布了三项疫苗试验的积极结果，一项针对新冠和流感，一项针对独立流感，另一项大剂量的新冠疫苗。诺瓦瓦克斯医药说，所有三种候选药物在2期试验中都产生了强劲的免疫反应，并显示出令人放心的初步安全性。该公司表示：“与季节性流感疫苗Fluad相比，独立的流感候选疫苗在所有四种菌株中实现了具有统计学意义的血凝抑制(HAI)抗体反应的31％至56％。”最高剂量的独立COVID疫苗取得了具有统计学意义的中和反应，比诺瓦瓦克斯医药的原型新冠疫苗高出约30％。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2334524465"}